Back HCV Disease Progression Transplant/Artificial Liver

Liver Transplant - HCV

AASLD 2014: AbbVie 3D Cures Recurrent HCV in Most Liver Transplant Recipients Without Cirrhosis

AbbVie's 3D regimen (newly named Viekirax + Exviera) demonstrated a sustained virological response rate of 97% for people with HCV genotype 1 recurrence after liver transplantation who had not yet developed advanced liver fibrosis or cirrhosis, according to results from the CORAL-I study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston and published in the November 11 advance edition of the New England Journal of Medicine.

alt

Read more:

AASLD 2014: DAAs Show Good Cure Rates and Liver Function Improvement for Transplant Recipients with Recurrent HCV

A variety of interferon-free regimens containing the direct-acting antivirals sofosbuvir (Sovaldi), simeprevir (Olysio), and daclatasvir (Daklinza) led to high sustained virological response rates, often improved liver function, and were generally safe and reasonably well-tolerated by liver transplant recipients with hepatitis C recurrence, one of the most difficult populations to treat, according to several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston.

alt

Read more:

AASLD 2014: HIV Positive People Have High Survival Rates After Liver Transplants Due to HCC

People with HIV -- most of whom were coinfected with hepatitis B or C -- generally had good outcomes after liver transplantation due to hepatocellular carcinoma (HCC), with 5-year survival rates similar to those of HIV negative transplant recipients and better than those of people who underwent other types of liver cancer treatment, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.

alt

Read more:

AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Post-Transplant HCV Recurrence

An interferon-free regimen of sofosbuvir plus ledipasvir (Harvoni) taken with ribavirin for 12 or 24 weeks led to sustained virological response in nearly all HCV genotype 1patients with fibrosis or less-advanced liver cirrhosis, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston. Response rates fell for people with more severe cirrhosis and signs of liver decompensation, but still a majority were cured.

alt

Read more:

Increased Distance Reduces Likelihood of Liver Transplant

alt

Living and receiving health care further away from a transplant center was associated with lower chances of being wait-listed for or receiving a liver transplant, according to a study of U.S. veterans described in the March 26 edition of JAMA.

Read more: